Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection targets Hard-to-Treat cancers

NCT ID NCT06171750

Recruiting now Disease control Sponsor: Ankyra Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid cancers, including lung and skin cancers, will take part. The study also tests the drug combined with another cancer medicine for a specific type of skin cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma skin neoplasm skin squamous cell carcinoma soft tissue neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CUTANEOUS SQUAMOUS CELL CARCINOMA CUTANEOUS TUMOR MALIGNANT SOLID TUMOR METASTASIS TO SOFT TISSUE METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER SOLID TUMOR SUBCUTANEOUS TUMOR

Contacts and locations

Locations

  • Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • National Cancer Institute

    RECRUITING

    Bethesda, Maryland, 20892, United States

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Cancer Institute

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.